Published in Clin Cancer Res on June 01, 1999
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. J Natl Cancer Inst (2013) 1.45
Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer (2005) 1.20
Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators. Brain Behav Immun (2008) 1.17
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med (2007) 1.11
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res (2004) 1.10
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol (2001) 1.04
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother (2012) 1.02
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol (2009) 1.02
Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med (2004) 1.02
Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg (2002) 1.00
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
Clinical uses of GM-CSF, a critical appraisal and update. Biologics (2008) 0.97
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology (2012) 0.94
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res (2015) 0.91
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol (2013) 0.90
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol (2004) 0.88
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol (2003) 0.88
Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res (2001) 0.88
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol (2012) 0.88
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine (2009) 0.88
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res (2008) 0.85
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
Immunomodulation of breast cancer via tumor antigen specific Th1. Cancer Res Treat (2009) 0.84
Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunol Immunother (2008) 0.84
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med (2010) 0.82
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs (2013) 0.82
Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology (2015) 0.82
Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res (2005) 0.81
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol (2016) 0.81
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine (2009) 0.81
Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules. Protein Sci (2005) 0.81
A new purification method for enhancing the immunogenicity of heat shock protein 70-peptide complexes. Oncol Rep (2012) 0.80
Progress in the development of a therapeutic vaccine for breast cancer. Breast Cancer (Dove Med Press) (2010) 0.80
Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol (2007) 0.79
Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu. Mol Immunol (2006) 0.79
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res (2001) 0.78
Gene therapy for carcinoma of the breast: Genetic immunotherapy. Breast Cancer Res (1999) 0.78
Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein. Cell Mol Immunol (2011) 0.78
Evolution of animal models in cancer vaccine development. Vaccine (2015) 0.77
A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes. Vaccines (Basel) (2015) 0.77
How much help does a vaccine-induced T-cell response need? J Clin Invest (2001) 0.75
Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iran J Basic Med Sci (2015) 0.75
Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself. Clin Immunol (2009) 0.75
Breast Cancer Immunotherapy. Maedica (Buchar) (2015) 0.75
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. Front Pharmacol (2017) 0.75
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97
Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell (1992) 5.54
Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 4.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 3.15
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med (1990) 2.12
IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol (1995) 2.10
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol (1992) 1.88
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology (1995) 1.85
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol (1995) 1.84
Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med (1987) 1.84
Activation of interleukin-1 beta by a co-induced protease. FEBS Lett (1989) 1.83
Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med (1991) 1.81
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature (1987) 1.75
IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol (1994) 1.70
Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol (1995) 1.69
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Regulation of human T cell proliferation by IL-7. J Immunol (1990) 1.58
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat (2000) 1.39
IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection. J Immunol (1996) 1.37
Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. J Biol Chem (1993) 1.34
The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. J Biol Chem (1995) 1.34
Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur J Immunol (1993) 1.34
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
Localization of human mononuclear cell interleukin 1. J Immunol (1987) 1.33
Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J Immunol (1990) 1.33
Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol (2000) 1.31
LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol (1998) 1.31
The effect of in vivo IL-7 deprivation on T cell maturation. J Exp Med (1995) 1.30
Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur J Immunol (1994) 1.29
CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur J Immunol (1996) 1.28
Oncogenic proteins as tumor antigens. Curr Opin Immunol (1996) 1.27
IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J Immunol (1993) 1.27
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol (1981) 1.27
Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med (1995) 1.25
A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis (1999) 1.25
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia (2003) 1.25
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
Interleukin-1 represents a new modality for the activation of extracellular signal-regulated kinases/microtubule-associated protein-2 kinases. J Biol Chem (1991) 1.24
Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol (1993) 1.20
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res (1994) 1.20
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood (2000) 1.18
Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol (1994) 1.17
Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL-1 restores Th function for antibody production. J Immunol (1989) 1.17
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol (1984) 1.15
CD40L: a multi-functional ligand. Semin Immunol (1993) 1.14
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res (1997) 1.13
Recombinant granulocyte-macrophage colony-stimulating factor restores deficient immune responses in mice with chronic Trypanosoma cruzi infections. J Immunol (1990) 1.12
The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol (1997) 1.12
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Regulation of murine T cell proliferation by B cell stimulatory factor-1. J Immunol (1987) 1.11
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol (1996) 1.10
Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol (1994) 1.10
H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol (1981) 1.10
Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res (1980) 1.08
Serodiagnosis of Chagas' disease by enzyme-linked immunosorbent assay using two synthetic peptides as antigens. J Clin Microbiol (1994) 1.08
Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes. J Immunol (1992) 1.06
A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol (1997) 1.06
T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol (1991) 1.05
T-cell growth factor P40 promotes the proliferation of myeloid cell lines and enhances erythroid burst formation by normal murine bone marrow cells in vitro. Blood (1990) 1.05
Bone marrow transplantation in patients aged 45 years and older. Blood (1986) 1.04
Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol (1985) 1.04
T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol (1991) 1.02
Antigen-reactive gamma delta T cells in human leishmaniasis. J Immunol (1993) 1.01
Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol (1995) 1.00
Trypanosoma cruzi acidic ribosomal P protein gene family. Novel P proteins encoding unusual cross-reactive epitopes. J Immunol (1993) 0.99
In vivo administration of interleukin-2. Contemp Top Mol Immunol (1985) 0.99
Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol (1998) 0.99
Mapping human T cell epitopes in leishmania gp63. Identification of cross-reactive and species-specific epitopes. J Immunol (1993) 0.99
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res (1995) 0.98
Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation (1982) 0.98
Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem (1997) 0.98
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med (1989) 0.97
Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol (1984) 0.97
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood (1995) 0.97
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol (1986) 0.97
In vitro responses to Leishmania antigens by lymphocytes from patients with leishmaniasis or Chagas' disease. J Clin Invest (1990) 0.96
Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol (1977) 0.96
T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A (1992) 0.95
IL-1 as adjuvant. Role of T cells in the augmentation of specific antibody production by recombinant human IL-1 alpha. J Immunol (1989) 0.94